In breast cancer, elevated PD-L1 levels are associated with unfavorable clinical outcomes and correlated with negative prognostic indicators, such as an increased proliferation index, larger tumor size, the absence of estrogen or progesterone receptors, HER2 positivity, and higher tumor grade [7,8,9,10]. Here, PGR is linked to neoplasm.